Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics, Inc. (AQST)
:AQST
RESEARCH TOOLSreports
Holding AQST?
Track your performance easily
AQST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.24 - $6.23
Previous CloseN/A
Volume606.88K
Average Volume (3M)1.59M
Market Cap
$281.74M
Enterprise Value$495.13M
Total Cash (Recent Filing)$9.21M
Total Debt (Recent Filing)$38.65M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Mar 11, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding91,178,190
10 Day Avg. Volume1,739,114
30 Day Avg. Volume1,590,381
Standard Deviation0.31
R-Squared0.21
Alpha0.00293
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.78
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.76
Enterprise Value/Revenue8.41
Enterprise Value/Gross Profit16.64
Enterprise Value/Ebitda-28.28
Forecast
1Y Price Target
$11.20Price Target Upside262.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Aquestive Therapeutics News
PremiumCompany Announcements
Aquestive Therapeutics Updates on Strategic Goals and Drug Progress
PremiumCompany Announcements
Aquestive Therapeutics Gains FDA Support for Anaphylm
PremiumCompany Announcements
Aquestive Therapeutics Announces Board and Committee Changes
PremiumCompany Announcements
Aquestive Therapeutics Advances Drug Candidates Amid ChallengesBulls Say, Bears Say
Bulls Say
Market PotentialThe company announced that the lead indication for AQST-108 is alopecia areata, which management believes can be a >$500MM revenue opportunity.
Product DifferentiationLibervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients with epilepsy between two and five years of age.
Regulatory ApprovalAquestive announced that it has received positive feedback from the FDA on submission plans for the Anaphylm NDA.
Bears Say
Market RisksRisks include faster-than-projected erosion of the Suboxone franchise by generics and inability to roll Libervant out to the broader U.S. market in a timely manner.
Product Launch DelaysRisks also include slower-than-projected market penetration of Libervant post-approval and failure with or delays to other candidates, especially Anaphylm and AQST-108.
Regulatory IssuesThe FDA cited 'review issues' regarding lower PK in the non-allergen exposure arm of the oral allergy syndrome challenge study and adequacy of data to support PK sustainability after single-dose Anaphylm.
---
Ownership Overview
14.95% Insiders
7.99% Mutual Funds
25.15% Other Institutional Investors
43.48% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AQST FAQ
What was Aquestive Therapeutics, Inc.’s price range in the past 12 months?
Aquestive Therapeutics, Inc. lowest stock price was $2.24 and its highest was $6.23 in the past 12 months.
What is Aquestive Therapeutics, Inc.’s market cap?
Aquestive Therapeutics, Inc.’s market cap is $281.74M.
When is Aquestive Therapeutics, Inc.’s upcoming earnings report date?
Aquestive Therapeutics, Inc.’s upcoming earnings report date is Mar 11, 2025 which is in 52 days.
How were Aquestive Therapeutics, Inc.’s earnings last quarter?
Aquestive Therapeutics, Inc. released its earnings results on Nov 04, 2024. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.118 by -$0.012.
Is Aquestive Therapeutics, Inc. overvalued?
According to Wall Street analysts Aquestive Therapeutics, Inc.’s price is currently Undervalued.
Does Aquestive Therapeutics, Inc. pay dividends?
Aquestive Therapeutics, Inc. does not currently pay dividends.
What is Aquestive Therapeutics, Inc.’s EPS estimate?
Aquestive Therapeutics, Inc.’s EPS estimate is -0.13.
How many shares outstanding does Aquestive Therapeutics, Inc. have?
Aquestive Therapeutics, Inc. has 91,178,190 shares outstanding.
What happened to Aquestive Therapeutics, Inc.’s price movement after its last earnings report?
Aquestive Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.118. Following the earnings report the stock price went down -7.573%.
Which hedge fund is a major shareholder of Aquestive Therapeutics, Inc.?
Among the largest hedge funds holding Aquestive Therapeutics, Inc.’s share is Woodline Partners LP. It holds Aquestive Therapeutics, Inc.’s shares valued at 4M.
---
Aquestive Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.20 (262.46% Upside)
$11.20 (262.46% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 247.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $213.8 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.09%
12-Months-Change
Fundamentals
Return on Equity
77.48%
Trailing 12-Months
Asset Growth
84.97%
Trailing 12-Months
Company Description
Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
---
AQST Company Deck
---
AQST Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in product development and market access, with positive clinical study outcomes and expanded commercial capabilities. However, financial challenges were evident with increased net losses and higher expenses.Read More>---
AQST Stock 12 Month Forecast
Average Price Target
$11.20
▲(262.46% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Karyopharm Therapeutics
―
EyePoint Pharmaceuticals
―
Verastem
―
Xeris Pharmaceuticals
―
Medicinova
―
Best Analysts Covering AQST
1 Year
1 Year Success Rate
18/35 ratings generated profit
1 Year Average Return
+40.71%
reiterated a buy rating 6 days ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 51.43% of your transactions generating a profit, with an average return of +40.71% per trade.
---